Phase 1 dose escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of TKI258 [dovitinib] in subjects with refractory or relapsed multiple myeloma
Phase of Trial: Phase I
Latest Information Update: 07 Sep 2007
At a glance
- Drugs Dovitinib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 07 Sep 2007 Status changed from recruiting to discontinued.
- 28 Oct 2006 New trial record.